Search

Your search keyword '"Savarino, EDOARDO VINCENZO"' showing total 437 results
Start Over Author "Savarino, EDOARDO VINCENZO"
437 results on '"Savarino, EDOARDO VINCENZO"'

1. Perception of the COVID-19 Pandemic Among Patients With Inflammatory Bowel Disease in the Time of Telemedicine: Cross-Sectional Questionnaire Study

Author

Zingone, Fabiana, Siniscalchi, Monica, Savarino, Edoardo Vincenzo, Barberio, Brigida, Cingolani, Linda, D'Incà, Renata, De Filippo, Francesca Romana, Camera, Silvia, and Ciacci, Carolina

Subjects
Computer applications to medicine. Medical informatics, R858-859.7, Public aspects of medicine, RA1-1270
Abstract

BackgroundAfter the COVID-19 outbreak, the Italian Government stopped most regular health care activity. As a result, patients with inflammatory bowel disease (IBD) had limited access to outpatient clinics and hospitals. ObjectiveThis study aimed to analyze the perception of the COVID-19 emergency among patients with IBD during the early weeks of the lockdown. MethodsWe invited adult patients with IBD from the University of Salerno (Campania, South Italy) and the University of Padua (Veneto, North Italy) by email to answer an ad hoc anonymous survey about COVID-19. We also collected data on demographic and disease characteristics. ResultsIn total, 167 patients with IBD from Padua and 83 patients from Salerno answered the survey (age: mean 39.7 years, SD 13.9 years; female: n=116, 46.4%). We found that patients with IBD were particularly worried about the COVID-19 pandemic (enough: 77/250, 30.8%; much/very much: 140/250, 56.0%), as they felt more vulnerable to COVID-19 due to their condition (enough: 70/250, 28.0%; much/very much: 109/250, 43.6%). Patients with IBD from the red zone of Veneto were more worried than patients from Campania (P=.001), and men felt more susceptible to the virus than women (P=.05). Additionally, remote medicine was appreciated more by younger patients than older patients (P=.04). ConclusionsThe results of our survey demonstrate that the lockdown had a significant impact on the psychological aspects of patients with IBD and suggest the need for increasing communication with patients with IBD (eg, through telemedicine) to ensure patients receive adequate health care, correct information, and proper psychological support.

Published
2020
Full Text
View/download PDF

3. The clinical impact of conventional therapies for adults and adolescents suffering from eosinophilic esophagitis, a type 2 inflammatory chronic disease, and their economic consequences in Italy: Systematic literature review and meta-analysis

Author

Canonica, Giorgio Walter, Mazziotti, Gherardo, Repici, Alessandro, Povero, Massimiliano, Castello, Luca, Pradelli, Lorenzo, Dobreva, Miryana, Fanelli, Francesca, Saab, Jean Pierre, and Savarino, Edoardo Vincenzo

Published
2025
Full Text
View/download PDF

4. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

Author

Abrahamovych, Orest, Abu-farsakh, Niazy, Afanasieva, Halyna, Akpinar, Hale, Al Kharrat, Houssam, Altintas, Engin, Altwegg, Romain, Andreev, Pavel, Aomatsu, Kazuki, Araki, Hiroshi, Argollo, Marjorie, Ariel, Federico, Armuzzi, Alessandro, Ashida, Toshifumi, Augustyn, Monika, Aumais, Guy, Azum, Martín, Baert, Filip, Balaz, Jozef, Balderramo, Domingo, Begun, Jakob, Berova, Temenuzhka, Billiauws, Lore, Blanco, Antonio, Bortlik, Martin, Bossa, Fabrizio, Bunkova, Elena, Cabello, Mercedes, Cao, Qian, Caprioli, Flavio, Cerqueira, Rute, Chachu, Karen, Chamouard, Patrick, Chen, Chunxiao, Chen, Yan, Chen, Baili, Chen, Dongfeng, Chen, Hong, Chen, Youxiang, Chen, Chou-chen, Cheon, Jaehee, Chen, Minhu, Chiu, Cheng-tang, Choi, Changhwan, Chow, Elizabeth, Cicala, Michele, Cintra, Aderson, Danilkiewicz, Wit, Datsenko, Olena, De Hertogh, Gert, De María, Julio, Del Valle Torrealba Medina, Leyanira, Deliang, Liu, Desreumaux, Pierre, Dewint, Pieter, Ding, Shigang, Doherty, Glen, Draganova, Raina, Dutré, Joris, Duvall, George, Egan, Laurence, Fahed, Julien, Fechner, Lars, Fedurco, Miroslav, Ferhat Celik, Aykut, Fernandez, Juan, Filip, Rafal, Fishman, Sigal, Flores, Cristina, Fogel, Ronald, Fowler, Sharyle, Francesconi, Carlos, Fujii, Toshimitsu, Fujiya, Mikihiro, Fukata, Masayuki, Fukuhara, Seiichiro, Furumoto, Yohei, G.Kiss, Gyula, Gachowski, Waldemar, Gao, Xiang, Gasbarrini, Antonio, Gawdis-wojnarska, Beata, Gaya, Daniel, Geccherle, Andrea, Gilletta De Saint Joseph, Cyrielle, Gimenez, Edgardo, Gionchetti, Paolo, Goldin, Eran, Golovchenko, Oleksandr, Gonciarz, Maciej, Gonen, Can, Gonzales, Chad, Gonzalez, Raquel, Gonzalez Segura, Gaston Julian, Gridnyev, Oleksiy, Gu, Fang, Gupta, Nitin, Gyokeres, Tibor, Haines, Melissa, Hebuterne, Xavier, Hedin, Charlotte, Hellstrom, Per, Hilmi, Ida Normiha, Hirai, Fumihito, Hisabe, Takashi, Hlavaty, Tibor, Hoentjen, Frank, Holtmann, Gerald, Horiki, Noriyuki, Horny, Ivo, Horvat, Gyula, Horvath, Frantisek, Hoshi, Namiko, Hosomi, Shuhei, Hospodarskyy, Ihor, Hou, Xiaohua, Hrdlicka, Ludek, Hu, Naizhong, Huang, Vivian, Huang, Caibin, Inaba, Tomoki, Ishiguro, Yoh, Ishihara, Shunji, Ishikawa, Takeshi, Iskandar, Heba, Israeli, Eran, Itaba, Soichi, Ivanishyn, Olha, Izbéki, Ferenc, Jain, Animesh, Jairath, Vipul, Jang, Byung Ik, Jiang, Chunmeng, Jones, Michael, Kagaya, Takashi, Kalimullina, Dilara, Karakina, Marina, Karatas, Ali, Kashimura, Hiroshi, Keret, Dan, Khovaeva, Yaroslava, Kierkus, Jaroslaw, Kim, Taeoh, Kim, Youngho, Kim, Hyo Jong, Klaus, Jochen, Kleczkowski, Dariusz, Klopocka, Maria, Kobayashi, Taku, Kobielusz-gembala, Iwona, Kojima, Yuichiro, Koo, Ja Seol, Kopon, Adam, Kopp, James, Koyama, Fumikazu, Koynarski, Vasil, Kravchenko, Tetiana, Kudo, Masatoshi, Kusunoki, Ryusaku, Kwon, Kwangan, Laclav, Martin, Lago, Paula, Laharie, David, Lasa, Juan, Lateef, Syed, Latinovic Radakovic, Tatjana, Lee, Kang Moon, Leszczyszyn, Jaroslaw, Li, Yan, Liu, Mei, Liu, Eashen, Lobaton Ortega, Triana, Lopatin, Denis, Lopes, Susana, Lovric Jovanovic, Mileva, Lubini, Marcio, Lukas, Milan, Maaser, Christian, Machytka, Evzen, Maemoto, Atsuo, Magro, Fernando, Marcet, Jorge, Marini, Eduardo, Marusawa, Hiroyuki, Matous, Jan, Matsumoto, Takayuki, Mendu, Shoba, Miao, Yinglei, Mihaly, Emese, Miheller, Pal, Ministro, Paula, Miyabayashi, Hideharu, Mohl, Wolfgang, Molnar, Martin, Moore, Gregory, Moran Faienzo, Gabriela, Morral, Eugeni Domenech, Motoya, Satoshi, Murali, Narayanachar, Mustaffa, Nazri Mohamad, Naem, Mohamed, Nakai, Katsuhiko, Nakajima, Koichi, Nakamoto, Yasunari, Nakamura, Masanao, Nancey, Stephane, Navaneethan, Udayakumar, Nawawi, Khairul Najmi Muhammad, Ninomiya, Tomoyuki, Novak, Janos, Oki, Motoji, Oliveira Santana, Genoile, Onizawa, Michio, Ono, Yohei, Osada, Taro, Osipenko, Marina, Owczarek, Danuta, Parente, Jose Miguel, Patel, Kamal, Patel, Bhaktasharan, Pedersen, Peder, Petroniene, Rima, Petrov, Asen, Petrova, Elina, Piquet, Marie-astrid, Pokrotnieks, Juris, Poroshina, Elena, Portela, Francisco, Pruthi, Jatinder S., Prystupa, Lyudmila, Pukitis, Aldis, Qiu, Yun, Rafalsky, Vladimir, Rainis, Tova, Ramos Junior, Odery, Rashid, Mohammed, Rayyan, Yasser, Reshetko, Olga, Ribeiro, Tarsila, Rivero, Montserrat, Roblin, Xavier, Romatowski, Jacek, Rowbotham, David, Ruffinengo, Orlando Enrique, Rydzewska-wyszkowska, Grazyna, Sablin, Oleg, Sai, Souken, Saibeni, Simone, Said, Rosaida Hj. Md., Sakuraba, Hirotake, Samaan, Mark, Sandborn, William, Saruta, Masayuki, Sauk, Jenny, Savarino, Edoardo Vincenzo, Schultz, Michael, Schulze, Joerg, Sedghi, Shahriar, Seidler, Ursula, Seksik, Philippe, Senturk, Omer, Shelton, Edward, Shimizu, Masahito, Shin, Sungjae, Shukla, Richa, Sigal, Michael, Silva Junior, Roberto, Simoes Neto, Joaquim, Siroky Jr., Milan, Smajstrla, Vit, Smid, Vaclav, Smiley, Sarah, Soledad Brunatto, Luciana, Stanislavchuk, Mykola, Stokesberry, David, Stone, Christian, Suiter, Daniel, Suzuki, Takayoshi, Svorcan, Petar, Takagi, Sho, Takagi, Tomohisa, Takamura, Masaaki, Takayama, Tetsuji, Takeuchi, Ken, Tanaka, Akihito, Tanaka, Hiroki, Tanash, Omar, Tang, Wen, Tankova, Ludmila, Teixeira Campos, Luciana, Thin, Lena, Tkachev, Alexander, Tolmanis, Ivars, Tsarynna, Nataliia, Tsonev, Nikolay, Tulassay, Zsolt, Ueo, Tetsuya, Unal, Nalan, Valuyskikh, Ekaterina, Van Dop, Willemijn, Vasilevskaya, Olga, Venugopal, Kannan, Verstockt, Bram, Viamonte, Manuel, Vyshyvanyuk, Vira, Wang, Bangmao, Wang, Xiaoyan, Wang, Jiangbin, Wang, Yufang, Wei, Shu-chen, Weisshof, Roni, Wisam, Sbeit, Wojcik, Katarzyna, Yakovlev, Alexey, Yasuda, Hiroshi, Ye, Byongduk, Yen, Hsu-heng, Yilmaz, Hasan, Yokoyama, Yoko, Yoon, Hyuk, Yoshida, Takeshi, Yurkiv, Andriy, Zaha, Osamu, Zaltman, Cyrla, Zhan, Qiang, Zhang, Hongjie, Zhang, Shutian, Zhu, Lanxiang, Zou, Duowu, Zou, Xiaoping, Zureikat, Firas, Rubin, David T, Allegretti, Jessica R, Panés, Julián, Shipitofsky, Nicole, Yarandi, Shadi S, Huang, Kuan-Hsiang Gary, Germinaro, Matthew, Wilson, Rebbecca, Zhang, Hongyan, Johanns, Jewel, Feagan, Brian G, Hisamatsu, Tadakazu, Lichtenstein, Gary R, Bressler, Brian, Peyrin-Biroulet, Laurent, Sands, Bruce E, and Dignass, Axel

Published
2025
Full Text
View/download PDF

6. Suboptimal disease control and contributing factors in Italian IBD patients: The IBD-PODCAST Study

Author

Calabrese, Emma, Onali, Sara, Variola, Angela, Ribaldone, Davide Giuseppe, Savarino, Edoardo Vincenzo, Viola, Anna, Saibeni, Simone, Conforti, Francesco Simone, Testa, Anna, Latella, Giovanni, Orlando, Ambrogio, Principi, Mariabeatrice, Privitera, Antonino Carlo, Guerra, Maria, Ceccarelli, Linda, Mocci, Giammarco, Boy, Davide, Piccarozzi, Maria Adelaide, Gualberti, Giuliana, Marando, Francesca, Gemignani, Lorenzo, and D'Amico, Ferdinando

Published
2025
Full Text
View/download PDF

8. The 1st EoETALY Consensus on the Diagnosis and Management of Eosinophilic Esophagitis–Current Treatment and Monitoring

Author

de Bortoli, Nicola, Visaggi, Pierfrancesco, Penagini, Roberto, Annibale, Bruno, Baiano Svizzero, Federica, Barbara, Giovanni, Bartolo, Ottavia, Battaglia, Edda, Di Sabatino, Antonio, De Angelis, Paola, Docimo, Ludovico, Frazzoni, Marzio, Furnari, Manuele, Iori, Andrea, Iovino, Paola, Lenti, Marco Vincenzo, Marabotto, Elisa, Marasco, Giovanni, Mauro, Aurelio, Oliva, Salvatore, Pellegatta, Gaia, Pesce, Marcella, Privitera, Antonino Carlo, Puxeddu, Ilaria, Racca, Francesca, Ribolsi, Mentore, Ridolo, Erminia, Russo, Salvatore, Sarnelli, Giovanni, Tolone, Salvatore, Zentilin, Patrizia, Zingone, Fabiana, Barberio, Brigida, Ghisa, Matteo, and Savarino, Edoardo Vincenzo

Published
2024
Full Text
View/download PDF

9. The 1st EoETALY Consensus on the Diagnosis and Management of Eosinophilic Esophagitis – Definition, Clinical Presentation and Diagnosis

Author

de Bortoli, Nicola, Visaggi, Pierfrancesco, Penagini, Roberto, Annibale, Bruno, Baiano Svizzero, Federica, Barbara, Giovanni, Bartolo, Ottavia, Battaglia, Edda, Di Sabatino, Antonio, De Angelis, Paola, Docimo, Ludovico, Frazzoni, Marzio, Furnari, Manuele, Iori, Andrea, Iovino, Paola, Lenti, Marco Vincenzo, Marabotto, Elisa, Marasco, Giovanni, Mauro, Aurelio, Oliva, Salvatore, Pellegatta, Gaia, Pesce, Marcella, Privitera, Antonino Carlo, Puxeddu, Ilaria, Racca, Francesca, Ribolsi, Mentore, Ridolo, Erminia, Russo, Salvatore, Sarnelli, Giovanni, Tolone, Salvatore, Zentilin, Patrizia, Zingone, Fabiana, Barberio, Brigida, Ghisa, Matteo, and Savarino, Edoardo Vincenzo

Published
2024
Full Text
View/download PDF

14. Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study

Author

Ribaldone, Davide Giuseppe, Parisio, Laura, Variola, Angela, Bossa, Fabrizio, Castiglione, Fabiana, Marzo, Manuela, Piazza, Nicole, Aratari, Annalisa, Savarino, Edoardo Vincenzo, Bodini, Giorgia, Mastronardi, Mauro, Micheli, Federica, Mazzuoli, Silvia, Ascolani, Marta, Viganò, Chiara, Cappello, Maria, Bezzio, Cristina, Ciccocioppo, Rachele, Scardino, Giulia, Sarli, Ennio, Pugliese, Daniela, Scaldaferri, Franco, Napolitano, Daniele, Todeschini, Alessia, Geccherle, Andrea, Colaci, Nicoletta, Guerra, Maria, Annese, Monica, Testa, Anna, Caiazzo, Anna, Conforti, Francesco Simone, Festa, Stefano, Lorenzon, Greta, Marra, Antonella, Magiotta, Ambra, Baccini, Flavia, Amato, Arnaldo, Poshnjari, Anxhela, Vernero, Marta, Caprioli, Flavio, and Caviglia, Gian Paolo

Published
2024
Full Text
View/download PDF

16. Italian guidelines for the management of irritable bowel syndrome: Joint Consensus from the Italian Societies of: Gastroenterology and Endoscopy (SIGE), Neurogastroenterology and Motility (SINGEM), Hospital Gastroenterologists and Endoscopists (AIGO), Digestive Endoscopy (SIED), General Medicine (SIMG), Gastroenterology, Hepatology and Pediatric Nutrition (SIGENP) and Pediatrics (SIP)

Author

Barbara, Giovanni, Cremon, Cesare, Bellini, Massimo, Corsetti, Maura, Di Nardo, Giovanni, Falangone, Francesca, Fuccio, Lorenzo, Galeazzi, Francesca, Iovino, Paola, Sarnelli, Giovanni, Savarino, Edoardo Vincenzo, Stanghellini, Vincenzo, Staiano, Annamaria, Stasi, Cristina, Tosetti, Cesare, Turco, Rossella, Ubaldi, Enzo, Zagari, Rocco Maurizio, Zenzeri, Letizia, and Marasco, Giovanni

Published
2023
Full Text
View/download PDF

17. Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab

Author

Bertani, Lorenzo, Barberio, Brigida, Fornili, Marco, Antonioli, Luca, Zanzi, Federico, Casadei, Cesare, Benvenuti, Laura, Facchin, Sonia, D'Antongiovanni, Vanessa, Lorenzon, Greta, Ceccarelli, Linda, Baglietto, Laura, de Bortoli, Nicola, Bellini, Massimo, Costa, Francesco, Savarino, Edoardo Vincenzo, and Fornai, Matteo

Published
2022
Full Text
View/download PDF

18. Management of Helicobacter pylori infection: Guidelines of the Italian Society of Gastroenterology (SIGE) and the Italian Society of Digestive Endoscopy (SIED)

Author

Benedetti, Antonio, Annibale, Bruno, Burra, Patrizia, Maida, Marcello Fabio, Luzza, Francesco, Ricciardiello, Luigi, Vecchi, Maurizio, Frulloni, Luca, Repici, Alessandro, Savarino, Edoardo Vincenzo, Pasquale, Luigi, Pisani, Antonio, Lamazza, Antonietta, Cengia, Gianpaolo, Ciliberto, Enrico, Conigliaro, Rita Luisa, Da Massa Carrara, Paola, Germanà, Bastianello, Romano, Marco, Gravina, Antonietta Gerarda, Eusebi, Leonardo Henry, Pellegrino, Raffaele, Palladino, Giovanna, Frazzoni, Leonardo, Dajti, Elton, Gasbarrini, Antonio, Di Mario, Francesco, and Zagari, Rocco Maurizio

Published
2022
Full Text
View/download PDF

19. The Dynamic Evolution of Eosinophilic Esophagitis.

Author

Farah, Amir, Assaf, Tarek, Hindy, Jawad, Abboud, Wisam, Mahamid, Mostafa, Savarino, Edoardo Vincenzo, and Mari, Amir

Subjects
EOSINOPHILIC esophagitis, THERAPEUTICS, GASTROESOPHAGEAL reflux, PROTON pump inhibitors, TISSUE remodeling
Abstract

Eosinophilic esophagitis (EoE) is a chronic, immune-mediated inflammatory condition of the esophagus characterized by eosinophilic infiltration, and hallmark symptoms of esophageal dysfunction such as dysphagia and food impaction. Over the past three decades, EoE has been recognized as a distinct clinical entity, distinguished from gastroesophageal reflux disease (GERD) through advancements in diagnostic techniques, particularly endoscopy with biopsy. The rising global prevalence of EoE reflects enhanced diagnostic awareness, evolving criteria, and environmental along with lifestyle changes. The etiology of EoE is multifactorial, involving genetic predispositions, immune dysregulation, the gut microbiome, and environmental triggers, including dietary allergens and aeroallergens. Key mechanisms include a type 2 helper T-cell (Th2)-driven immune response, epithelial barrier dysfunction, and genetic variants such as CAPN14 and TSLP. Chronic inflammation leads to tissue remodeling, fibrosis, and esophageal narrowing, contributing to disease progression and complications. Management strategies have evolved to include dietary elimination, proton pump inhibitors, topical corticosteroids, biologics, and endoscopic interventions for fibrostenotic complications. Emerging therapies targeting cytokines such as interleukin (IL)-4, IL-5, and IL-13, alongside novel diagnostic tools like the esophageal string test and Cytosponge, offer promising avenues for improved disease control and non-invasive monitoring. Long-term surveillance combining endoscopic and histological evaluations with biomarkers and non-invasive tools is critical to optimizing outcomes and preventing complications. Future research should address gaps in understanding the role of the esophageal microbiome, refine therapeutic approaches, and develop personalized strategies to improve disease management and patient quality of life. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

20. The Revised Reflux Symptom Index (R-RSI): Development, Internal and External Validation Study.

Author

Nacci, Andrea, de Bortoli, Nicola, Capobianco, Silvia, Simoni, Federica, Giusti, Tamanai, Visaggi, Pierfrancesco, Barillari, Maria Rosaria, Savarino, Edoardo Vincenzo, Frazzoni, Marzio, Berrettini, Stefano, Fattori, Bruno, and Bastiani, Luca

Abstract

Introduction: This study proposes a revised version of the Reflux Symptom Index (R-RSI), a seventeen-item questionnaire that was revised to increase the suspicion of laryngopharyngeal reflux disease (LPRD). Methods: Internal validation involved 213 participants, comprising 160 subjects without a previous LPRD diagnosis and 53 subjects with a self-reported previous diagnosis of LPRD with or without gastroesophageal reflux disease (GERD). Test-retest reliability and internal consistency were calculated. For the external validation, 56 patients (independent from the previous cohort) were enrolled to explore the R-RSI screening properties and determine a cutoff using 24-h MII-pH as the gold standard. Results: R-RSI test-retest reliability was high, both for the total score (ICC: 0.970) and for each item (ranging from 0.876 to 0.980). Cronbach's alpha was 0.910, indicating excellent internal consistency of the questionnaire. Participants with a previous self-reported diagnosis scored significantly higher (mean 24.94 ± 7.4; median 26, IQR 20–29) than those without a previous diagnosis (mean 4.66 ± 5.3; median 4, IQR 1–6) (p value <0.0001). Participants with both previous LPRD and GERD diagnoses had higher scores (27.20 ± 7.8) compared to those with only LPRD (21.77 ± 5.5) (p value = 0.003). Using 24-h MII-pH diagnosis as a gold standard, the optimal R-RSI cutoff point was determined to be 18, with a sensitivity of 84.5% and a specificity of 81.8%, positive predictive value of 95%, and negative predictive value of 60%. Conclusions: Our results suggest that the R-RSI may be useful to suspect LPRD, with or without GERD. The R-RSI is a self-administered patient-reported outcome questionnaire that demonstrates excellent reliability and high screening properties. Employing a cutoff of ≥18 in the R-RSI can assist in diagnosing and monitoring LPRD. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

22. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

Author

Afzali, Anita, Aitova, Lilia, Aldeguer i Mante, Xavier, Allez, Matthieu, Altorjay, István, Argüelles Arias, Federico, Armuzzi, Alessandro, Augustyn, Monika, Bafutto, Mauro, Barrio, Jesus, Begun, Jakob, Behrend, Clint, Bezemer, Geert, Bonnaud, Guillaume, Brankovic, Marija, Byung, Ik Jang, Calvet Calvo, Xavier, Chachu, Karen, Chebli, Julio Maria Fonseca, Cheon, Jae Hee, Cichoz-Lach, Halina, Clark, Larry, Cummings, Fraser, Dalal, Kunal, Danese, Silvio, De Boer, Nanne, De Lourdes Ferrari, Maria, Désilets, Etienne, Dugalic, Predrag, Duvall, George, Fedorishina, Olga, Filip, Rafal, Flores, Cristina, Fogel, Ronald, Fon, James, Frankel, Michael, Friedenberg, Keith, Fries, Walter, Galina, Vassileva, Gietka, Piotr, Goel, Rishi, Hasselblatt, Peter, Herfarth, Hans, Herszényi, László, Hindryckx, Pieter, Hoentjen, Frank, Horjus Talabur Horje, Carmen, Iduru, Satish, Irving, Peter, Isfort, Robert, Jairath, Vipul, Jones, Michael, Kalimullina, Dilara, Katz, Jeffry, Kaur, Manreet, Khurana, Sunil K, Kim, Joo Sung, Kim, Youngho, Kleczkowski, Dariusz, Knezevic, Slavko, Knoll, Aaron, Korman, Louis Y, Kotzev, Iskren, Kulyapin, Andrey, Lee, Kang Moon, Leemreis, Desiree, Leszczyszyn, Jaroslaw, Limdi, Jimmy, Lissauer, Jack, Loftus, Edward, Malecka-Panas, Ewa, Marshall, John, Mihály, Emese, Milan, Lukas, Monteleone, Giovanni, Nagorni, Aleksandar, Owczarek, Danuta, Palekar, Nichole, Panaccione, Remo, Park, Young Soo, Park, Sang Hyoung, Parra, Rogério, Patai, Árpád, Patel, Kamal, Patel, Bhaktasharan, Pershko, Anatoly, Petrova, Elina, Pineton de Chambrun, Guillaume, Randall, Charles, Riestra Menendez, Sabino, Ritter, Timothy, Rivero, Montserrat, Roblin, Xavier, Rocca, Rodolfo, Romatowski, Jacek, Rydzewska, Grazyna, Saibeni, Simone, Salzberg, Bruce, Sarles, Harry, Saunders, John, Savarino, Edoardo Vincenzo, Serclova, Zuzana, Shchukina, Oksana, Siegel, Jonathan, Soofi, Najm, Sparrow, Miles, Stokesberry, David, Suiter, Daniel, Svorcan, Petar, Tkachev, Alexander, Tsonev, Nikolay, Tünde, Kristóf, Ulbrych, Jan, Vanasek, Tomas, Varga, Márta, Vermeire, Severine, Vicente Lidon, Raquel, Weiss, Michael L, Wesley, Emma, Winstead, Nathaniel, Wojcik, Katarzyna, Wypych, Joanna, Zaltman, Cyrla, Zdena, Zadorova, Sands, Bruce E, Irving, Peter M, Hoops, Timothy, Izanec, James L, Gao, Long-Long, Gasink, Christopher, Greenspan, Andrew, Hanauer, Stephen B, Kuehbacher, Tanja, Lewis, James D, Loftus, Edward V, Jr, Mihaly, Emese, Scherl, Ellen, Shchukina, Oksana B, and Sandborn, William J

Published
2022
Full Text
View/download PDF

24. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

Author

Aguilar, Humberto, Ahmad, Tariq, Akriviadis, Evangelos, Aldeguer Mante, Xavier, Allez, Matthieu, Altorjay, Istvan, Ananthakrishnan, Ashwin, Andersen, Vibeke, Andreu Garcia, Montserrat, Armuzzi, Alessandro, Aumais, Guy, Avni-Biron, Irit, Axler, Jeffrey, Ayub, Kamran, Jr., Baert, Filip, Bafutto, Mauro, Bamias, George, Bassan, Isaac, Baum, Curtis, Beaugerie, Laurent, Behm, Brian, Bekal, Pradeep, Bennett, Michael, Bermejo San Jose, Fernando, Bernstein, Charles, Bettenworth, Dominik, Bhaskar, Sudhir, Biancone, Livia, Bilir, Bahri, Blaeker, Michael, Bloom, Stuart, Bohman, Verle, Jr., Bosques Padilla, Francisco Javier, Bossuyt, Peter, Bouhnik, Yoram, Bouma, Gerd, Bourdages, Raymond, Brand, Stephan, Bressler, Brian, Brückner, Markus, Buening, Carsten, Carbonnel, Franck, Caves, Thomas, Chapman, Jonathon, Cheon, Jae Hee, Chiba, Naoki, Chioncel, Camelia, Christodoulou, Dimitrios, Clodi, Martin, Cohen, Albert, Corazza, Gino Roberto, Corlin, Richard, Cosintino, Rocco, Cummings, Fraser, Dalal, Robin, Danese, Silvio, De Maeyer, Marc, De Magalhães Francesconi, Carlos Fernando, De Silva, Aminda, Debinski, Henry, Desreumaux, Pierre, Dewit, Olivier, D'Haens, Geert, Di Felice Boratto, Sandra, Ding, John Nik, Dixon, Tyler, Dryden, Gerald, Jr., Du Vall, George Aaron, Ebert, Matthias, Echarri Piudo, Ana, Ehehalt, Robert, Elkhashab, Magdy, Ennis, Craig, Etzel, Jason, Fallingborg, Jan, Feagan, Brian, Fejes, Roland, Ferraz de Campos Mazo, Daniel, Ferreira de Almeida Borges, Valéria, Fischer, Andreas, Fixelle, Alan, Fleisher, Mark, Fowler, Sharyle, Freilich, Bradley, Friedenberg, Keith, Fries, Walter, Fulop, Csaba, Fumery, Mathurin, Fuster, Sergio, G Kiss, Gyula, Garcia Lopez, Santiago, Gassner, Sonja, Gill, Kanwar, Gilletta de Saint Joseph, Cyrielle, Ginsburg, Philip, Gionchetti, Paolo, Goldin, Eran, Goldis, Adrian-Eugen, Gomez Jaramillo, Hector Alejandro, Gonciarz, Maciej, Gordon, Glenn, Green, Daniel, Grimaud, Jean-Charles, Guajardo Rodriguez, Rogelio, Gurzo, Zoltan, Gutierrez, Alexandra, Gyökeres, Tibor, Hahm, Ki Baik, Hanauer, Stephen, Hanson, John, Harlan III, William, Hasselblatt, Peter, Hayee, Buhussain, Hebuterne, Xavier, Hendy, Peter, Heyman, Melvin, Higgins, Peter, Hilal, Raouf, Hindryckx, Pieter, Hoentjen, Frank, Hoffmann, Peter, Holtkamp-Endemann, Frank, Holtmann, Gerald, Horvat, Gyula, Howaldt, Stefanie, Huber, Samuel, Ibegbu, Ikechukwu, Iborra Colomino, Maria Isabel, Irving, Peter, Isaacs, Kim, Jagarlamudi, Kiran, Jain, Rajesh, Jankiel Miszputen, Sender, Jansen, Jeroen, Jones, Jennifer, Juillerat, Pascal, Karagiannis, John, Karyotakis, Nicholas, Kaser, Arthur, Katz, Lior, Katz, Seymour, Katz, Leo, Kaur, Nirmal, Kazenaite, Edita, Khanna, Reena, Khurana, Sunil, Kim, Joo Sung, Kim, Young-Ho, Kim, Sung Kook, Kim, Dongwoo, Klaus, Jochen, Kleczkowski, Dariusz, Kohout, Pavel, Korczowski, Bartosz, Kouklakis, Georgios, Koutroubakis, Ioannis, Krause, Richard, Kristof, Tunde, Kronborg, Ian, Krummenerl, Annette, Kupcinskas, Limas, Laborda Molteni, Jorge, Laharie, David, Lahat-zok, Adi, Lee, Jonghun, Lee, Kang-Moon, Leong, Rupert, Levine, Henry, Limdi, Jimmy, Lindsay, James, Lodhia, Nilesh, Loftus, Edward, Longman, Randy, Lopez Serrano, Pilar, Louis, Edouard, Louzada Pereira, Maria Helena, Lowe, John, Lueth, Stefan, Lukas, Milan, Maconi, Giovanni, Macrae, Finlay, Madi-Szabo, Laszlo, Mahadevan-Velayos, Uma, Malluta, Everson Fernando, Mana, Fazia, Mannon, Peter, Mantzaris, Gerasimos, Marin Jimenez, Ignacio, Martin Arranz, Maria Dolores, Mateescu, Radu-Bogdan, Mazzoleni, Felipe, Meder, Agnieszka, Melzer, Ehud, Mertens, Jessica, Mimidis, Konstantinos, Mitchell, Brent, Molnar, Tamas, Moore, Gregory, Morales Garza, Luis Alonso, Mountifield, Reme, Muls, Vinciane, Murray, Charles, Nagy, Bela, Neurath, Markus, Nguyen, Augustin, Panaccione, Remo, Pandak, William, Panes Diaz, Julian, Park, Jihye, Pastorelli, Luca, Patel, Bhaktasharan, Peck-Radosavljevic, Markus, Pecsi, Gyula, Peerani, Farhad, Perez Gisbert, Javier, Pesta, Martin, Petryka, Robert, Peyrin-Biroulet, Laurent, Phillips, Raymond, Pierik, Marieke, Pratha, Vijayalakshmi, Prochazka, Vlastimil, Racz, Istvan, Radford-Smith, Graham, Ramos Castañeda, Daniel, Ramos Júnior, Odery, Regula, Jaroslaw, Reimund, Jean-Marie, Robbins, Bryan, Roblin, Xavier, Rogai, Francesca, Rogler, Gerhard, Rozciecha, Jerzy, Rubin, David, Ruiz Flores, Azalia Yuriria, Rupinski, Maciej, Rydzewska, Grazyna, Saha, Sumona, Saibeni, Simone, Salamon, Agnes, Sallo, Zoltan, Salzberg, Bruce, Samuel, Douglas, Samuel, Sunil, Sandborn, William, Savarino, Edoardo Vincenzo, Schirbel, Anja, Schnabel, Robert, Schreiber, Stefan, Scott, John, Sedghi, Shahriar, Seibold, Frank, Seidelin, Jakob, Seidler, Ursula, Shaban, Ahmad, Shafran, Ira, Sheikh, Aasim, Sherman, Alex, Shirin, Haim, Smolinski, Patryk, Song, Geun Am, Soufleris, Konstantinos, Speight, Alexander, Staessen, Dirk, Stallmach, Andreas, Staun, Michael, Stein, Daniel, Steinhart, Hillary, Stifft, Jonathas, Stokesberry, David, Sturm, Andreas, Sultan, Keith, Szekely, Gyorgy, Tagore, Kuldeep, Tanno, Hugo, Thin, Lena, Thiwan, Syed, Thomas, Carlton, Tichy, Michal, Toth, Gabor Tamas, Tulassay, Zsolt, Ulbrych, Jan, Valentine, John, Varga, Marta, Vasconcellos, Eduardo, Vaughn, Byron, Velasco, Brenda, Velazquez, Francisco, Vermeire, Severine, Villa, Erica, Vincze, Aron, Vogelsang, Harald, Volfova, Miroslava, Vuitton, Lucine, Vyhnalek, Petr, Wahab, Peter, Walldorf, Jens, Waterman, Mattitiahu, Weber, John, Weiss, L. Michael, Wiechowska-Kozlowska, Anna, Wiesner, Elise, Witthoeft, Thomas, Wohlman, Robert, Wozniak-Stolarska, Barbara, Yacyshyn, Bruce, Ye, Byong-Duk, Younes, Ziad, Yukie Sassaki, Lígia, Zaltman, Cyrla, Zeuzem, Stefan, Hart, Ailsa, Long, Millie, Loftus, Edward V, Jr, Ostad-Saffari, Elham, Scalori, Astrid, Oh, Young S, Tole, Swati, Chai, Akiko, Pulley, Jennifer, Lacey, Stuart, and Sandborn, William J

Published
2022
Full Text
View/download PDF

25. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study

Author

Aboo, Nazimuddin, Ahmad, Tariq, Aldeguer Mante, Xavier, Allez, Matthieu, Almer, Sven, Altwegg, Romain, Andreu Garcia, Montserrat, Arasaradnam, Ramesh, Ardizzone, Sandro, Armuzzi, Alessandro, Arnott, Ian, Aumais, Guy, Avni-Biron, Irit, Barrow, Peter, Beales, Ian, Bermejo San Jose, Fernando, Bezuidenhout, Abraham, Biancone, Livia, Blaeker, Michael, Bloom, Stuart, Bokemeyer, Bernd, Bossa, Fabrizio, Bossuyt, Peter, Bouguen, Guillaume, Bouhnik, Yoram, Bouma, Gerd, Bourdages, Raymond, Bourreille, Arnaud, Boustiere, Christian, Brabec, Tomas, Brand, Stephan, Buening, Carsten, Buisson, Anthony, Cadiot, Guillaume, Calvet Calvo, Xavier, Carbonnel, Franck, Carpio, Daniel, Cheon, Jae Hee, Chiba, Naoki, Chioncel, Camelia, Cimpoeru, Nicoleta-Claudia, Clodi, Martin, Corazza, Gino Roberto, Cosintino, Rocco, Cotter, Jose, Creed, Thomas, Cummings, Fraser, Danese, Silvio, de' Angelis, Gian Luigi, De Maeyer, Marc, Desai, Milind, Desilets, Etienne, Desreumaux, Pierre, Dewit, Olivier, D'Haens, Geert, Dinter, Johanna, Dobru, Ecaterina Daniela, Douda, Tomas, Dumitrascu, Dan Lucian, Ebert, Matthias, Echarri Piudo, Ana, Elkhashab, Magdy, Eun, Chang Soo, Feagan, Brian, Fejes, Roland, Fidalgo, Catarina, Fishman, Sigal, Flourié, Bernard, Fowler, Sharyle, Fries, Walter, Fulop, Csaba, Fumery, Mathurin, G Kiss, Gyula, Gassner, Sonja, Gaya, Daniel, Germanà, Bastianello, Gheorghe, Liliana Simona, Gilletta de Saint Joseph, Cyrielle, Gionchetti, Paolo, Goldis, Adrian-Eugen, Gonçalves, Raquel, Grimaud, Jean-Charles, Gyökeres, Tibor, Hagege, Herve, Haidar, Andrei, Hartmann, Heinz, Hasselblatt, Peter, Hayee, Buhussain, Hebuterne, Xavier, Hellström, Per, Hindryckx, Pieter, Hlavova, Helena, Hoentjen, Frank, Howaldt, Stefanie, Hrdlicka, Ludek, Huh, Kyu Chan, Iborra Colomino, Maria Isabel, Ionita-Radu, Florentina, Irving, Peter, Jahnsen, Jørgen, Jang, ByungIk, Jansen, Jeroen, Jeon, Seong Woo, Jover Martinez, Rodrigo, Juillerat, Pascal, Karlén, Per, Kaser, Arthur, Keil, Radan, Kejariwal, Deepak, Keret, Dan, Khanna, Reena, Kim, Dongwoo, Kim, Duk Hwan, Kim, Hyo-Jong, Kim, Hyun-Soo, Kim, Joo Sung, Kim, Kueongok, Kim, Kyung-Jo, Kim, Sung Kook, Kim, Young-Ho, Klaus, Jochen, Kohn, Anna, Kojecky, Vladimir, Koo, Ja Seol, Kozak, Robert, Kremer, Milan, Kristof, Tunde, Kruger, Frederik, Laharie, David, Lahat-zok, Adi, Landa, Evgeny, Lee, Jonghun, Lee, Kang-Moon, Lee, Kook Lae, Lee, YooJin, Lenze, Frank, Lim, Wee Chian, Limdi, Jimmy, Lindsay, James, Lopez Serrano, Pilar, Louis, Edouard, Lueth, Stefan, Lukas, Milan, Maconi, Giovanni, Mana, Fazia, Mann, Steven, Mansfield, John, Marchi, Santino, Marino, Marco, Marshall, John, Martin Arranz, Maria Dolores, Mateescu, Radu-Bogdan, McLaughlin, John, McLaughlin, Simon, Melzer, Ehud, Mertens, Jessica, Mitrut, Paul, Molnar, Tamas, Muls, Vinciane, Munuswamy, Pushpakaran, Murray, Charles, Naftali, Timna, Naidoo, Visvakuren, Nanabhay, Yusuf, Negreanu, Lucian, Nguyen, Augustin, Ochsenkuehn, Thomas, Orlando, Ambrogio, Panaccione, Remo, Panes Diaz, Julian, Paritsky, Maya, Park, Dong Il, Park, Jihye, Pastorelli, Luca, Peck-Radosavljevic, Markus, Peerani, Farhad, Perez Gisbert, Javier, Peyrin-Biroulet, Laurent, Picon, Laurence, Pierik, Marieke, Ponich, Terry, Portela, Francisco, Prins, Maartens Jeroen, Racz, Istvan, Rahman, Khan Fareed, Reimund, Jean-Marie, Reinshagen, Max, Roblin, Xavier, Rocca, Rodolfo, Rogai, Francesca, Rogler, Gerhard, Salamon, Agnes, Salazar, Ennaliza, Sallo, Zoltan, Samuel, Sunil, Sans Cuffi, Miquel de los Santos, Savarino, Edoardo Vincenzo, Savarino, Vincenzo, Savoye, Guillaume, Schreiber, Stefan, Seicean, Andrada, Selinger, Christian, Serra, David Martins, Shim, Hang Hock, Shin, SungJae, Siegmund, Britta, Siffledeen, Jesse, Simmonds, Wayne, Smid, Jan, Sollano, Jose, Song, Geun Am, Speight, Alexander, Sporea, Ioan, Staessen, Dirk, Stancu, George, Steel, Alan, Stepek, David, Stoica, Victor, Sturm, Andreas, Szekely, Gyorgy, Tan, Teck Kiang, Taxonera Samso, Carlos, Thomson, John, Tichy, Michal, Toth, Gabor Tamas, Tulassay, Zsolt, Vangeli, Marcello, Varga, Marta, Vieira, Ana, Viennot, Stephanie, Villa, Erica, Vitek, Petr, Vogelsang, Harald, Vyhnalek, Petr, Wahab, Peter, Walldorf, Jens, Ye, Byong Duk, Ziady, Christopher, Colombel, Jean-Frederic, Gisbert, Javier P, Hayee, Bu'hussain, Reinisch, Walter, Tyrrell, Helen, Oh, Young S, Tole, Swati, Chai, Akiko, Chamberlain-James, Kirsten, and Tang, Meina Tao

Published
2022
Full Text
View/download PDF

26. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

Author

Rubin, David T, Allegretti, Jessica R, Panés, Julián, Shipitofsky, Nicole, Yarandi, Shadi S, Huang, Kuan-Hsiang Gary, Germinaro, Matthew, Wilson, Rebbecca, Zhang, Hongyan, Johanns, Jewel, Feagan, Brian G, Hisamatsu, Tadakazu, Lichtenstein, Gary R, Bressler, Brian, Peyrin-Biroulet, Laurent, Sands, Bruce E, Dignass, Axel, Abrahamovych, Orest, Abu-farsakh, Niazy, Afanasieva, Halyna, Akpinar, Hale, Al Kharrat, Houssam, Altintas, Engin, Altwegg, Romain, Andreev, Pavel, Aomatsu, Kazuki, Araki, Hiroshi, Argollo, Marjorie, Ariel, Federico, Armuzzi, Alessandro, Ashida, Toshifumi, Augustyn, Monika, Aumais, Guy, Azum, Martín, Baert, Filip, Balaz, Jozef, Balderramo, Domingo, Begun, Jakob, Berova, Temenuzhka, Billiauws, Lore, Blanco, Antonio, Bortlik, Martin, Bossa, Fabrizio, Bunkova, Elena, Cabello, Mercedes, Cao, Qian, Caprioli, Flavio, Cerqueira, Rute, Chachu, Karen, Chamouard, Patrick, Chen, Chunxiao, Chen, Yan, Chen, Baili, Chen, Dongfeng, Chen, Hong, Chen, Youxiang, Chen, Chou-chen, Cheon, Jaehee, Chen, Minhu, Chiu, Cheng-tang, Choi, Changhwan, Chow, Elizabeth, Cicala, Michele, Cintra, Aderson, Danilkiewicz, Wit, Datsenko, Olena, De Hertogh, Gert, De María, Julio, Del Valle Torrealba Medina, Leyanira, Deliang, Liu, Desreumaux, Pierre, Dewint, Pieter, Ding, Shigang, Doherty, Glen, Draganova, Raina, Dutré, Joris, Duvall, George, Egan, Laurence, Fahed, Julien, Fechner, Lars, Fedurco, Miroslav, Ferhat Celik, Aykut, Fernandez, Juan, Filip, Rafal, Fishman, Sigal, Flores, Cristina, Fogel, Ronald, Fowler, Sharyle, Francesconi, Carlos, Fujii, Toshimitsu, Fujiya, Mikihiro, Fukata, Masayuki, Fukuhara, Seiichiro, Furumoto, Yohei, G.Kiss, Gyula, Gachowski, Waldemar, Gao, Xiang, Gasbarrini, Antonio, Gawdis-wojnarska, Beata, Gaya, Daniel, Geccherle, Andrea, Gilletta De Saint Joseph, Cyrielle, Gimenez, Edgardo, Gionchetti, Paolo, Goldin, Eran, Golovchenko, Oleksandr, Gonciarz, Maciej, Gonen, Can, Gonzales, Chad, Gonzalez, Raquel, Gonzalez Segura, Gaston Julian, Gridnyev, Oleksiy, Gu, Fang, Gupta, Nitin, Gyokeres, Tibor, Haines, Melissa, Hebuterne, Xavier, Hedin, Charlotte, Hellstrom, Per, Hilmi, Ida Normiha, Hirai, Fumihito, Hisabe, Takashi, Hlavaty, Tibor, Hoentjen, Frank, Holtmann, Gerald, Horiki, Noriyuki, Horny, Ivo, Horvat, Gyula, Horvath, Frantisek, Hoshi, Namiko, Hosomi, Shuhei, Hospodarskyy, Ihor, Hou, Xiaohua, Hrdlicka, Ludek, Hu, Naizhong, Huang, Vivian, Huang, Caibin, Inaba, Tomoki, Ishiguro, Yoh, Ishihara, Shunji, Ishikawa, Takeshi, Iskandar, Heba, Israeli, Eran, Itaba, Soichi, Ivanishyn, Olha, Izbéki, Ferenc, Jain, Animesh, Jairath, Vipul, Jang, Byung Ik, Jiang, Chunmeng, Jones, Michael, Kagaya, Takashi, Kalimullina, Dilara, Karakina, Marina, Karatas, Ali, Kashimura, Hiroshi, Keret, Dan, Khovaeva, Yaroslava, Kierkus, Jaroslaw, Kim, Taeoh, Kim, Youngho, Kim, Hyo Jong, Klaus, Jochen, Kleczkowski, Dariusz, Klopocka, Maria, Kobayashi, Taku, Kobielusz-gembala, Iwona, Kojima, Yuichiro, Koo, Ja Seol, Kopon, Adam, Kopp, James, Koyama, Fumikazu, Koynarski, Vasil, Kravchenko, Tetiana, Kudo, Masatoshi, Kusunoki, Ryusaku, Kwon, Kwangan, Laclav, Martin, Lago, Paula, Laharie, David, Lasa, Juan, Lateef, Syed, Latinovic Radakovic, Tatjana, Lee, Kang Moon, Leszczyszyn, Jaroslaw, Li, Yan, Liu, Mei, Liu, Eashen, Lobaton Ortega, Triana, Lopatin, Denis, Lopes, Susana, Lovric Jovanovic, Mileva, Lubini, Marcio, Lukas, Milan, Maaser, Christian, Machytka, Evzen, Maemoto, Atsuo, Magro, Fernando, Marcet, Jorge, Marini, Eduardo, Marusawa, Hiroyuki, Matous, Jan, Matsumoto, Takayuki, Mendu, Shoba, Miao, Yinglei, Mihaly, Emese, Miheller, Pal, Ministro, Paula, Miyabayashi, Hideharu, Mohl, Wolfgang, Molnar, Martin, Moore, Gregory, Moran Faienzo, Gabriela, Morral, Eugeni Domenech, Motoya, Satoshi, Murali, Narayanachar, Mustaffa, Nazri Mohamad, Naem, Mohamed, Nakai, Katsuhiko, Nakajima, Koichi, Nakamoto, Yasunari, Nakamura, Masanao, Nancey, Stephane, Navaneethan, Udayakumar, Nawawi, Khairul Najmi Muhammad, Ninomiya, Tomoyuki, Novak, Janos, Oki, Motoji, Oliveira Santana, Genoile, Onizawa, Michio, Ono, Yohei, Osada, Taro, Osipenko, Marina, Owczarek, Danuta, Parente, Jose Miguel, Patel, Kamal, Patel, Bhaktasharan, Pedersen, Peder, Petroniene, Rima, Petrov, Asen, Petrova, Elina, Piquet, Marie-astrid, Pokrotnieks, Juris, Poroshina, Elena, Portela, Francisco, Pruthi, Jatinder S., Prystupa, Lyudmila, Pukitis, Aldis, Qiu, Yun, Rafalsky, Vladimir, Rainis, Tova, Ramos Junior, Odery, Rashid, Mohammed, Rayyan, Yasser, Reshetko, Olga, Ribeiro, Tarsila, Rivero, Montserrat, Roblin, Xavier, Romatowski, Jacek, Rowbotham, David, Ruffinengo, Orlando Enrique, Rydzewska-wyszkowska, Grazyna, Sablin, Oleg, Sai, Souken, Saibeni, Simone, Said, Rosaida Hj. Md., Sakuraba, Hirotake, Samaan, Mark, Sandborn, William, Saruta, Masayuki, Sauk, Jenny, Savarino, Edoardo Vincenzo, Schultz, Michael, Schulze, Joerg, Sedghi, Shahriar, Seidler, Ursula, Seksik, Philippe, Senturk, Omer, Shelton, Edward, Shimizu, Masahito, Shin, Sungjae, Shukla, Richa, Sigal, Michael, Silva Junior, Roberto, Simoes Neto, Joaquim, Siroky Jr., Milan, Smajstrla, Vit, Smid, Vaclav, Smiley, Sarah, Soledad Brunatto, Luciana, Stanislavchuk, Mykola, Stokesberry, David, Stone, Christian, Suiter, Daniel, Suzuki, Takayoshi, Svorcan, Petar, Takagi, Sho, Takagi, Tomohisa, Takamura, Masaaki, Takayama, Tetsuji, Takeuchi, Ken, Tanaka, Akihito, Tanaka, Hiroki, Tanash, Omar, Tang, Wen, Tankova, Ludmila, Teixeira Campos, Luciana, Thin, Lena, Tkachev, Alexander, Tolmanis, Ivars, Tsarynna, Nataliia, Tsonev, Nikolay, Tulassay, Zsolt, Ueo, Tetsuya, Unal, Nalan, Valuyskikh, Ekaterina, Van Dop, Willemijn, Vasilevskaya, Olga, Venugopal, Kannan, Verstockt, Bram, Viamonte, Manuel, Vyshyvanyuk, Vira, Wang, Bangmao, Wang, Xiaoyan, Wang, Jiangbin, Wang, Yufang, Wei, Shu-chen, Weisshof, Roni, Wisam, Sbeit, Wojcik, Katarzyna, Yakovlev, Alexey, Yasuda, Hiroshi, Ye, Byongduk, Yen, Hsu-heng, Yilmaz, Hasan, Yokoyama, Yoko, Yoon, Hyuk, Yoshida, Takeshi, Yurkiv, Andriy, Zaha, Osamu, Zaltman, Cyrla, Zhan, Qiang, Zhang, Hongjie, Zhang, Shutian, Zhu, Lanxiang, Zou, Duowu, Zou, Xiaoping, and Zureikat, Firas

Abstract

Interleukin-23 inhibition is effective in treating ulcerative colitis. Guselkumab is a dual-acting, human IgG1, interleukin-23p19 subunit inhibitor that potently neutralises interleukin-23 and can bind to CD64. We aimed to evaluate the efficacy and safety of guselkumab as induction and maintenance therapy in patients with ulcerative colitis.

Published
2025
Full Text
View/download PDF

27. Advancing therapeutic frontiers: a pipeline of novel drugs for luminal and perianal Crohn's disease management.

Author

Bertin, Luisa, Crepaldi, Martina, Zanconato, Miriana, Lorenzon, Greta, Maniero, Daria, de Barba, Caterina, Bonazzi, Erica, Facchin, Sonia, Scarpa, Marco, Ruffolo, Cesare, Angriman, Imerio, Buda, Andrea, Zingone, Fabiana, Barberio, Brigida, and Savarino, Edoardo Vincenzo

Subjects
CROHN'S disease, PPAR-gamma agonists, INFLAMMATORY bowel diseases, CLINICAL trials, TUMOR necrosis factors
Abstract

Crohn's disease (CD) is a chronic, complex inflammatory disorder of the gastrointestinal tract that presents significant therapeutic challenges. Despite the availability of a wide range of treatments, many patients experience primary non-response, secondary loss of response, or adverse events, limiting the overall effectiveness of current therapies. Clinical trials often report response rates below 60%, partly due to stringent inclusion criteria. Emerging therapies that target novel pathways offer promise in overcoming these limitations. This review explores the latest investigational drugs in phases I, II, and III clinical trials for treating both luminal and perianal CD. We highlight promising therapies that target known mechanisms, including selective Janus kinase inhibitors, anti-adhesion molecules, tumor necrosis factor inhibitors, and IL-23 selective inhibitors. In addition, we delve into novel therapeutic strategies such as sphingosine-1-phosphate receptor modulators, miR-124 upregulators, anti-fractalkine (CX3CL1), anti-TL1A, peroxisome proliferator-activated receptor gamma agonists, TGFBRI/ALK5 inhibitors, anti-CCR9 agents, and other innovative small molecules, as well as combination therapies. These emerging approaches, by addressing new pathways and mechanisms of action, have the potential to surpass the limitations of existing treatments and significantly improve CD management. However, the path to developing new therapies for inflammatory bowel disease (IBD) is fraught with challenges, including complex trial designs, ethical concerns regarding placebo use, recruitment difficulties, and escalating costs. The landscape of IBD clinical trials is shifting toward greater inclusivity, improved patient diversity, and innovative trial designs, such as adaptive and Bayesian approaches, to address these challenges. By overcoming these obstacles, the drug development pipeline can advance more effective, accessible, and timely treatments for CD. Plain language summary: Crohn's disease: hope on the horizon with new therapies in development Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) that affects millions of people worldwide. Many people with CD do not respond well to current treatments, and researchers are looking for new options. Clinical trials are research studies that test new drugs and treatments. They are carefully designed to protect the safety of participants. Several new approaches to treating CD are currently undergoing clinical trials. These include drug candidates in various stages of development, from early research to large-scale phase III trials. Cellular therapies are also being tested, involving the injection of cells locally or intravenously to promote healing. Crohn's disease (CD) is a long-term condition that causes inflammation in the digestive tract. It can be difficult to treat, as current medications don't always work for everyone, and some people experience side effects or stop responding to treatment over time. Even in clinical trials, where new treatments are tested, less than 60% of patients show positive responses. Researchers are working on new treatments that target different pathways involved in Crohn's disease. This review looks at drugs being tested in early to late-stage clinical trials. Some of these drugs target well-known pathways, like JAK inhibitors and IL-23 blockers, while others focus on newer areas, such as specific receptors or molecules involved in inflammation. These emerging therapies aim to provide better, longer-lasting relief for patients. However, developing new treatments isn't easy. Clinical trials for Crohn's disease face many challenges, including complicated trial designs, ethical concerns about using placebos, difficulties in recruiting enough patients, and high costs. To overcome these issues, researchers are exploring more flexible and inclusive trial methods, which could help bring new treatments to patients more quickly and efficiently. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn's Disease: A Retrospective, Multicentre Study.

Author

Farkas, Bernadett, Bessissow, Talat, Limdi, Jimmy K., Sethi-Arora, Karishma, Kagramanova, Anna, Knyazev, Oleg, Bezzio, Cristina, Armuzzi, Alessandro, Lukas, Milan, Michalopoulos, George, Chaskova, Elena, Savarino, Edoardo Vincenzo, Castiglione, Fabiana, Rispo, Antonio, Schäfer, Eszter, Saibeni, Simone, Filip, Rafal, Attauabi, Mohamed, Fousekis, Fotios S., and Bacsur, Péter

Subjects
CROHN'S disease, ULCERATIVE colitis, DISEASE remission, C-reactive protein, CALPROTECTIN
Abstract

Background/Objectives: Data on the real-world effectiveness and safety of selective JAK inhibitors (JAKis) in ulcerative colitis (UC) and Crohn's disease (CD) are limited. Methods: We conducted a multicentre, retrospective study to assess clinical, biochemical, and endoscopic outcomes of selective JAKis in bio-experienced UC and CD. Results: A total of 246 patients (mean age: 40.5 ± 14.5 years; 131 UC and 115 CD) were included with a median follow-up of 7.5 months. Among the CD patients receiving upadacitinib (n = 115), 76.2% achieved clinical remission (CR) at week 12. Furthermore, 59.5% of the upadacitinib-treated UC patients (n = 100) experienced CR at week 8. Corticosteroid-free CR (CSFCR) was achieved by 76.9% of the CD patients and 80.6% of the UC patients at week 24, while 50.0% and 36.1% experienced endoscopic remission. At week 52, 66.7% of the CD and 86.2% of the UC patients achieved CSFCR, whereas 54.5% and 52.9% had endoscopic remission. In UC, the effectiveness of upadacitinib was not compromised by prior tofacitinib failure, while the upadacitinib-treated CD patients with stricturing and penetrating disease were less likely to achieve CR by the end of the induction phase (p = 0.04). C-reactive protein (p[CD] < 0.0001; p[UC] < 0.0001) and faecal calprotectin (p[CD] < 0.0001; p[UC] = 0.02) decreased significantly in both patient groups as early as week 2. Among the filgotinib-treated UC patients (n = 31), 28.6% were in CR at week 12. At week 24 and 52, 59.1% and 60% achieved CSFCR, while 0.0% and 20.0% had endoscopic remission. Both C-reactive protein (p = 0.04) and faecal calprotectin (p = 0.04) decreased significantly by week 12. Hyperlipidaemia (9.7–9.8%) was the most common adverse event. Conclusions: Selective JAKis are rapidly effective and safe for treating refractory, moderate-to-severe CD and UC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Risk Factors and Postoperative Outcomes in Pouchitis Following Restorative Proctocolectomy: An 18-Year Single-Center Study.

Author

Bertin, Luisa, Nasrallah, Mohamad, Redavid, Carlo, Bonazzi, Erica, Maniero, Daria, Lorenzon, Greta, De Barba, Caterina, Facchin, Sonia, Scarpa, Marco, Ruffolo, Cesare, Angriman, Imerio, Buda, Andrea, Fassan, Matteo, Lacognata, Carmelo, Barberio, Brigida, Zingone, Fabiana, and Savarino, Edoardo Vincenzo

Subjects
CROHN'S disease, INFLAMMATORY bowel diseases, PREOPERATIVE risk factors, BIOTHERAPY, RESTORATIVE proctocolectomy, ULCERATIVE colitis
Abstract

Background/Objectives: Restorative proctocolectomy with ileo-anal pouch anastomosis (IPAA) remains the preferred surgical treatment for ulcerative colitis (UC). However, complications like pouchitis can occur. This study aimed to describe patients who underwent IPAA for inflammatory bowel disease (IBD) at Padua Hospital from 2005 to 2023 and identify risk factors for pouchitis. Secondary objectives included evaluating the effectiveness of biological therapy in chronic antibiotic-refractory pouchitis (CARP), Crohn's disease of the pouch (CDP), and Crohn's-like inflammation of the pouch (CDLPI), and assessing risk factors for pouch failure. Methods: This retrospective, observational study included 109 patients whose data were collected from medical records. Univariate logistic regression was used to analyze associations between preoperative and postoperative factors and outcomes such as acute pouchitis and pouch failure. The effectiveness of biological therapy was assessed by measuring changes in the Pouchitis Disease Activity Index (PDAI) and the Modified Pouchitis Disease Activity Index (mPDAI) over a 12-month treatment period. Results: Univariate logistic regression revealed significant associations between preoperative extraintestinal manifestations (OR 3.569, 95% CI 1.240–10.720), previous diagnosis of Crohn's disease (OR 10.675, 95% CI 1.265–90.089), and transmural inflammation at cross-sectional imaging before surgery (OR 3.453, 95% CI 1.193–9.991) with an acute pouchitis risk. Pouch failure was significantly associated with a previous diagnosis of Crohn's disease (OR 9.500, 95% CI 1.821–49.571) and post-surgical fistulas (OR 41.597, 95% CI 4.022–430.172). Biological therapy led to a significant reduction in the PDAI score in patients with CARP, decreasing from a median of 10 to 4 (p = 0.006). Similarly, in patients with CDP or CDLPI, the mPDAI score was significantly reduced from a median of 9 to 1 (p = 0.034), with remission achieved in 5/6 (83.3%) of these patients. Conclusions: This study provides valuable insights into the management of IPAA patients and highlights the importance of early identification and treatment of risk factors for pouchitis and failure. Biological therapy demonstrated significant effectiveness in reducing disease activity in patients with CARP, CDP, and CDLPI, suggesting its role as a crucial component in managing these complications. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. The Esophageal Microbiota in Esophageal Health and Disease.

Author

Bonazzi, Erica, Lorenzon, Greta, Maniero, Daria, De Barba, Caterina, Bertin, Luisa, Barberio, Brigida, Salvador, Renato, Valmasoni, Michele, Zingone, Fabiana, Ghisa, Matteo, and Savarino, Edoardo Vincenzo

Subjects
BARRETT'S esophagus, ESOPHAGUS diseases, EOSINOPHILIC esophagitis, GASTROESOPHAGEAL reflux, ESOPHAGEAL cancer
Abstract

The esophagus, traditionally viewed as a sterile conduit, is now recognized as a dynamic habitat for diverse microbial communities. The emerging evidence suggests that the esophageal microbiota plays an important role in maintaining esophageal health and contributing to disease. The aim of this systematic review was to synthesize the current knowledge on the esophageal microbiota composition, its variation between healthy individuals and those with esophageal diseases, and the potential mechanisms through which these microorganisms influence esophageal pathology. A systematic literature search was conducted using multiple databases, including PubMed, Scopus, and Web of Science, to identify relevant studies published up to July 2024. The inclusion criteria encompassed original research articles that used molecular techniques to characterize the esophageal microbiota in human subjects, comparing healthy individuals with patients affected by esophageal conditions such as gastroesophageal reflux disease (GERD), Barrett's esophagus, eosinophilic esophagitis, and esophageal cancer. The primary outcomes were the composition and diversity of the esophageal microbiota, and the secondary outcomes included the correlations between microbial profiles and disease states. The esophageal microbiota of healthy individuals was dominated by Gram-positive bacteria, particularly Streptococcus. Conversely, the esophageal microbiota is considerably altered in disease states, with decreased microbial diversity and specific microbial signatures associated with these conditions, which may serve as biomarkers for disease progression and as targets for therapeutic intervention. However, the heterogeneous study designs, populations, and analytical methods underscore the need for standardized approaches in future research. Understanding the esophageal microbiota's role in health and disease could guide microbiota-based diagnostics and treatments, offering novel avenues for managing esophageal conditions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Standard length of peroral endoscopic myotomy (POEM) for achalasia: a systematic review and meta-analysis.

Author

Vespa, Edoardo, Barchi, Alberto, Mandarino, Francesco Vito, Fasulo, Ernesto, Fratto, Maria Caterina, Passaretti, Sandro, Azzolini, Francesco, Savarino, Edoardo Vincenzo, and Danese, Silvio

Subjects
ESOPHAGEAL motility, ESOPHAGEAL achalasia, TECHNICAL reports, MYOTOMY, SUBGROUP analysis (Experimental design)
Abstract

Peroral endoscopic myotomy (POEM) is an established treatment for achalasia, yet there is still a lack of technical standardization. No clear definition of 'long', 'standard', or 'short' POEM exists to date. We conducted a systematic review with meta-analysis to analyze current POEM length standards. We included studies reporting technical details of POEM, in which no definite or comparative myotomy length was intentionally adopted (standard myotomy). The primary outcome was the pooled mean total myotomy length. Sub-group analyses were performed to explore heterogeneity across studies. From the initial 7172 records, 31 studies with 3023 patients were included. Pooled mean of total myotomy length was 10.39 cm (95% CI 10.06–10.71; I2 99.3%). Pooled mean of esophageal and gastric myotomy length, provided by 17 studies, was 7.11 cm (95% CI 6.51–7.71; I2 99.8%) and 2.81 cm (95% CI 2.41–3-22; I2 99.8%), respectively. On subgroup analysis for achalasia subtypes, pooled mean length in non-spastic achalasia (type I and II) was 10.17 cm (95% CI 9.91–10.43; I2 94.2%), while in type III it was 14.02 cm (95% CI 10.59–17.44; I2 98.9%). Pooled mean myotomy length for studies conducted between 2014–2020 was 10.53 cm (95% CI, 10.22–10.84; I2 99.1%) and 9.74 cm (95% CI, 7.95–11.54; I2 99.7%) in 2021–2022. Myotomy length during a 'standard' POEM is 10.4 cm, remaining over 10 cm in non-spastic achalasia. The high heterogeneity across studies confirms that the POEM technique needs further standardization. We found no significant time trend towards adopting short POEM, despite recent evidence supporting its use. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Evaluating Vonoprazan for the treatment of erosive GERD and heartburn associated with GERD in adults.

Author

Marabotto, Elisa, Calabrese, Francesco, Pasta, Andrea, Visaggi, Pierfrancesco, de Bortoli, Nicola, Mari, Amir, Tolone, Salvatore, Ghisa, Matteo, Bertin, Luisa, Savarino, Vincenzo, and Savarino, Edoardo Vincenzo

Subjects
NON-erosive reflux disease, PROTON pump inhibitors, GASTROESOPHAGEAL reflux, DISEASE management, CHRONIC diseases, HEARTBURN
Abstract

Introduction: Gastroesophageal reflux disease (GERD) is a common debilitating chronic disease presenting in two main forms based on esophageal mucosal appearance, the erosive reflux disease (ERD) and the non-erosive reflux disease (NERD). Acid secretion is a key factor in the disease pathogenesis and management. Potent acid-suppressant drugs have been manufactured since the mid of 1970s, initially with histamine-H2-receptors antagonists, and later, inhibitors of the proton pump (H+-K+-ATPase).More recently, potassium-competitive acid blockers (p-CABs), particularlyVonoprazan, have been introduced. Vonoprazan has shown high efficacy and safety profiles and exhibits several advantages that allow to overcome shortcomings of proton pump inhibitors (PPIs). Areas covered: In this review, we provide an updated summary of Vonoprazan pharmacodynamics and its role in clinical practice for the management of erosive esophagitis and GERD-related heartburn. Moreover, we discuss characteristics of Vonoprazan that allow to bypass some limitations of the older PPIs. Expert opinion: Long-term safety and efficacy of Vonoprazan have already been demonstrated for the induction and maintenance of ERD, preventing nocturnal acid breakthrough, reducing reflux symptoms in non-responder to standard therapy. Ongoing and future studies are expected to further elucidate its long-term benefits and potential applications in other acid-related disorders. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Pharmacological management of gastro-esophageal reflux disease: state of the art in 2024.

Author

Visaggi, Pierfrancesco, Bertin, Luisa, Pasta, Andrea, Calabrese, Francesco, Ghisa, Matteo, Marabotto, Elisa, Ribolsi, Mentore, Savarino, Vincenzo, de Bortoli, Nicola, and Savarino, Edoardo Vincenzo

Subjects
PHARMACOLOGY, GASTROESOPHAGEAL reflux, BARRETT'S esophagus, PROTON pump inhibitors, ANALYTICAL mechanics
Abstract

Introduction: Gastroesophageal reflux disease (GERD) is a chronic disease of the esophagus characterized by the regurgitation of stomach contents into the esophagus, causing troublesome symptoms and/or complications. Among patients with GERD, around 30% of patients have visible mucosal damage, while 70% have normal esophageal mucosa. Accordingly, the optimal pharmacological treatment of GERD should address different disease manifestations, including symptoms, the mucosal damage when present, and possible chronic complications, including strictures, Barrett's esophagus, and esophageal adenocarcinoma. Areas covered: Available medical treatments for GERD include proton pump inhibitors (PPIs), potassium-competitive acid blockers (PCABs), histamine receptor antagonists (H2-RAs), prokinetics, and mucosal protectants, such as alginates, hyaluronic acid/chondroitin-sulfate, and poliprotect. Each compound has its own advantages and disadvantages, and knowledge of expected benefits and tips for their use is paramount for the success of treatment. In addition, the appropriateness of indications for initiating treatment is also crucial to achieve positive results when managing GERD patients. Expert opinion: PPIs, PCABs, H2-RAs, prokinetics, and mucosal protectants can all be used in patients with GERD, but careful assessment of patients' characteristics as well as advantages and disadvantages of each therapeutic compound is essential to ensure successful treatment of GERD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Comparing Point-of-Care Technology to ELISA Testing for Infliximab and Adalimumab Levels in Adult Inflammatory Bowel Disease Patients: A Prospective Pilot Study.

Author

Bonazzi, Erica, Maniero, Daria, Lorenzon, Greta, Bertin, Luisa, Bray, Kurtis, Bahur, Bayda, Barberio, Brigida, Zingone, Fabiana, and Savarino, Edoardo Vincenzo

Subjects
DRUG monitoring, INFLAMMATORY bowel diseases, ENZYME-linked immunosorbent assay, POINT-of-care testing, TURNAROUND time
Abstract

Introduction: Therapeutic drug monitoring (TDM) has proven to be a valuable strategy for optimizing biologic therapies, among which are anti-tumor necrosis factor (anti-TNF) treatments in inflammatory bowel disease (IBD). In particular, reactive TDM has been shown to manage treatment failures more cost-effectively than empirical dose adjustments for anti-TNF drugs. However, several challenges currently impede the widespread adoption of TDM in clinical practice, particularly addressing the delay between sample collection and result availability. To overcome this limitation, the use of point-of-care technology tests (POCTs) is a potential solution. Point-of-care technology tests are medical diagnostic tests performed at the site of patient care to provide immediate results, allowing for quicker decision-making and treatment. The current standard of care (SOC) for drug level measurement relies on the enzyme-linked immunosorbent assay (ELISA), a method that is time-consuming and requires specialized personnel. This study aims to evaluate a novel, user-friendly, and efficient POCT method (ProciseDx Inc.) and compare its performance with the SOC ELISA in assessing infliximab and adalimumab levels in blood samples from IBD patients. Methods: In this prospective, single-center study, we collected blood samples from IBD patients, both CD and UC, receiving infliximab (87 IBD patients; 50% UC and 50% CD) or adalimumab (60 patients; 14% UC and 48% CD) and we analyzed the blood's drugs levels using both the ProciseDx Analyzer POC and the SOC ELISA. We examined the correlation between the two methods using statistical analyses, including the Deming regression test. Additionally, we assessed the ease of use, turnaround time, and overall practicality of the POCT in a clinical setting. Results: The ProciseDx test demonstrated a strong correlation with the SOC ELISA for measuring both infliximab and adalimumab levels. In particular, the overall correlation between the ProciseDx POCT and the ELISA assessments showed an r coefficient of 0.83 with an R squared value of 0.691 (95% CI 0.717–0.902) for IFX measurements, and an r coefficient of 0.85 with an R squared value of 0.739 (95% CI 0.720–0.930). Conclusions: the ProciseDx POC test offers significantly faster turnaround times and is more straightforward to use, making it a viable alternative for routine clinical monitoring. Despite its promising potential, further refinement and validation of the ProciseDx test are necessary to ensure its effectiveness across diverse patient populations and clinical settings. Future research should focus on optimizing the POC tests' performance and evaluating its long-term impact on IBD management. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Short-Chain Fatty Acids and Human Health: From Metabolic Pathways to Current Therapeutic Implications

Author

Facchin, Sonia, primary, Bertin, Luisa, additional, Bonazzi, Erica, additional, Lorenzon, Greta, additional, De Barba, Caterina, additional, Barberio, Brigida, additional, Zingone, Fabiana, additional, Maniero, Daria, additional, Scarpa, Marco, additional, Ruffolo, Cesare, additional, Angriman, Imerio, additional, and Savarino, Edoardo Vincenzo, additional

Published
2024
Full Text
View/download PDF

38. The Role of High-Resolution Manometry Prior to and Following Antireflux Surgery: The Padova Consensus

Author

Salvador, Renato, primary, Pandolfino, John E., additional, Costantini, Mario, additional, Gyawali, C Prakash, additional, Keller, Jutta, additional, Mittal, Sumeet, additional, Roman, Sabine, additional, Savarino, Edoardo Vincenzo, additional, Tatum, Roger, additional, Tolone, Salvatore, additional, Zerbib, Frank, additional, Capovilla, Giovanni, additional, Jain, Anand, additional, Kathpalia, Priya, additional, Provenzano, Luca, additional, and Yadlapati, Rena, additional

Published
2024
Full Text
View/download PDF

39. Refractory Crohn’s Disease: Perspectives, Unmet Needs and Innovations

Author

Bertin,Luisa, Crepaldi,Martina, Zanconato,Miriana, Lorenzon,Greta, Maniero,Daria, De Barba,Caterina, Bonazzi,Erica, Facchin,Sonia, Scarpa,Marco, Ruffolo,Cesare, Angriman,Imerio, Buda,Andrea, Zingone,Fabiana, Savarino,Edoardo Vincenzo, Barberio,Brigida, Bertin,Luisa, Crepaldi,Martina, Zanconato,Miriana, Lorenzon,Greta, Maniero,Daria, De Barba,Caterina, Bonazzi,Erica, Facchin,Sonia, Scarpa,Marco, Ruffolo,Cesare, Angriman,Imerio, Buda,Andrea, Zingone,Fabiana, Savarino,Edoardo Vincenzo, and Barberio,Brigida

Abstract

Luisa Bertin,1 Martina Crepaldi,1 Miriana Zanconato,1 Greta Lorenzon,1 Daria Maniero,1 Caterina De Barba,1 Erica Bonazzi,1 Sonia Facchin,1 Marco Scarpa,2 Cesare Ruffolo,2 Imerio Angriman,2 Andrea Buda,3 Fabiana Zingone,1 Edoardo Vincenzo Savarino,1 Brigida Barberio1 1Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; 2Chirurgia Generale 3 Unit, Azienda Ospedale Università di Padova, Padua, Italy; 3Gastroenterology Unit, Department of Oncological Gastrointestinal Surgery, Feltre, ItalyCorrespondence: Edoardo Vincenzo Savarino, Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy, Tel +39-049-8217749, Fax +39-049-8760820, Email edoardo.savarino@unipd.itAbstract: Crohn’s disease (CD) is a complex, chronic inflammatory bowel disease characterized by unpredictable flare-ups and periods of remission. Despite advances in treatment, CD remains a significant health burden, leading to substantial direct healthcare costs and out-of-pocket expenses for patients, especially in the first-year post-diagnosis. The impact of CD on patients’ quality of life is profound, with significant reductions in physical, emotional, and social well-being. Despite advancements in therapeutic options, including biologics, immunomodulators, and small molecules, many patients struggle to achieve or maintain remission, leading to a considerable therapeutic ceiling. This has led to an increased focus on novel and emerging treatments. This context underscores the importance of exploring advanced and innovative treatment options for managing refractory CD. By examining the latest approaches, including immunomodulators, combination therapies, stem cell therapies, and emerging treatments like fecal microbiota transplantation and dietary interventions, there is an opportunity to gain a comprehensive understanding of how best to address and manage refractory cases of CD. Keywords

Published
2024

40. Economic evaluation of two therapeutic sequences in the first-line treatment of moderate to severe active ulcerative rectocolitis in Italy

Author

Armeni, Patrizio, Compagnucci , Elena, Fiorino, Gionata, Lolli, Vincenzo, Mazzone , Grazia, Orlando, Ambrogio, Principi, Mariabeatrice, Ravasio, Roberto, Rizzello, Fernando, Savarino, Edoardo Vincenzo, Tombari, Francesca, Armeni, Patrizio, Compagnucci , Elena, Fiorino, Gionata, Lolli, Vincenzo, Mazzone , Grazia, Orlando, Ambrogio, Principi, Mariabeatrice, Ravasio, Roberto, Rizzello, Fernando, Savarino, Edoardo Vincenzo, and Tombari, Francesca

Abstract

Background: Vedolizumab (VDZ) and infliximab are used to treat moderate to severe ulcerative colitis (UC). The choice of the drug to use at first-line is often based on a combination of clinical and economic factors. The cost of treatment pathway is rarely considered. Therefore, this cost-consequence analysis (CCA) investigated the overall costs of treatment pathway for vedolizumab followed by infliximab (VDZ → IFX) compared to infliximab followed by vedolizumab (IFX → VDZ). Methods: We used a published cost-consequence model (CCM), based on a targeted literature search reporting the time-on-treatment data for vedolizumab or infliximab in UC in first and second-line of treatment. CCM time horizon was defined by the length of treatment sequences. Considering the Italian hospital perspective, the CCA evaluated the biologic drugs acquisition costs, drug administration costs, hospitalization costs, switch costs, colectomy costs and third-line treatment costs. Third-line options included colectomy, tofacitinib, ustekinumab or dose escalation of second-line biologic. Results: Over the 5.2-year time horizon (duration of the longer VDZ → IFX pathway), the mean cost per patient of VDZ → IFX pathway was slightly lower than the mean cost per patient of IFX → VDZ pathway (€ 86,339 vs 89,636). The CCM predicted that using VDZ as first-line treatment delayed the time to costly third-line therapies compared to first-line using IFX (VDZ-first-line median time-on-treatment 3.6-years and IFX-second-line 1.6-years; IFX-first-line 1.4-years and VDZ-second-line 2.3-years and third-line 1.5-years). Conclusion: The CCA showed that a biologic treatment pathway that begins with first-line vedolizumab is not more expensive than one beginning with first-line infliximab and delayed the time to costly third-line.

Published
2024

41. The Clinical Spectrum of Gastroesophageal Reflux Disease: Facts and Fictions

Author

Marabotto, Elisa, Pasta, Andrea, Calabrese, Francesco, Ribolsi, Mentore, Mari, Amir, Savarino, Vincenzo, and Savarino, Edoardo Vincenzo

Abstract

Background:This review addresses the intricate spectrum of gastroesophageal reflux disease (GERD), a condition affecting 10–30% of the Western population. GERD is characterized by the backflow of gastric contents into the esophagus, causing typical and atypical symptoms. Its pathophysiology involves various factors such as hiatal hernia, esophageal motor disorders, and dietary triggers. The review explores the complexities of GERD spectrum, including nonerosive reflux disease (NERD), reflux hypersensitivity (RH), and functional heartburn (FH). Summary:The diagnostic process for GERD, based on the Lyon Consensus 2.0 criteria, encompasses clinical evaluation, endoscopy, and functional tests, including pH-impedance and wireless-pH monitoring. NERD, a significant subset of GERD, is defined by reflux symptoms and abnormal reflux burden without mucosal damage. RH, classified under functional esophageal disorders by Rome IV criteria, presents with typical esophageal symptoms associated with reflux but lacks of structural, inflammatory, or motor causes. FH is identified by heartburn with normal endoscopy, reflux testing, and esophageal manometry results. The management of RH and FH, focusing on reducing esophageal hypersensitivity, varies from standard GERD treatments. Key Messages:The review emphasizes the necessity of personalized treatment strategies due to the complexity and overlap of GERD subtypes. It highlights the importance of a multidisciplinary approach, involving gastroenterologists, psychologists, and other specialists, to improve patient outcomes and quality of life. The article underscores that understanding the distinctions and overlaps among NERD, RH, and FH is crucial for effective management, and the need for innovative approaches in diagnosis and treatment to address the unique challenges of each subtype.

Published
2024
Full Text
View/download PDF

42. Association between Ustekinumab Trough Levels, Serum IL-22, and Oncostatin M Levels and Clinical and Biochemical Outcomes in Patients with Crohn’s Disease

Author

Bertin, Luisa, primary, Barberio, Brigida, additional, Gubbiotti, Alessandro, additional, Bertani, Lorenzo, additional, Costa, Francesco, additional, Ceccarelli, Linda, additional, Visaggi, Pierfrancesco, additional, Bodini, Giorgia, additional, Pasta, Andrea, additional, Sablich, Renato, additional, Urbano, Maria Teresa, additional, Ferronato, Antonio, additional, Buda, Andrea, additional, De Bona, Manuela, additional, Del Corso, Giulio, additional, Massano, Alessandro, additional, Angriman, Imerio, additional, Scarpa, Marco, additional, Zingone, Fabiana, additional, and Savarino, Edoardo Vincenzo, additional

Published
2024
Full Text
View/download PDF

43. Economic evaluation of two therapeutic sequences in the first-line treatment of moderate to severe active ulcerative rectocolitis in Italy

Author

Armeni, Patrizio, primary, Compagnucci, Elena, additional, Fiorino, Gionata, additional, Lolli, Vincenzo, additional, Mazzone, Grazia, additional, Orlando, Ambrogio, additional, Principi, Mariabeatrice, additional, Ravasio, Roberto, additional, Rizzello, Fernando, additional, Savarino, Edoardo Vincenzo, additional, and Tombari, Francesca, additional

Published
2024
Full Text
View/download PDF

44. The Role of the FODMAP Diet in IBS

Author

Bertin, Luisa, primary, Zanconato, Miriana, additional, Crepaldi, Martina, additional, Marasco, Giovanni, additional, Cremon, Cesare, additional, Barbara, Giovanni, additional, Barberio, Brigida, additional, Zingone, Fabiana, additional, and Savarino, Edoardo Vincenzo, additional

Published
2024
Full Text
View/download PDF

45. De Novo Gastroesophageal Reflux Disease Symptoms Are Infrequent after Sleeve Gastrectomy at 2-Year Follow-Up Using a Comprehensive Preoperative Esophageal Assessment

Author

Tolone, Salvatore, primary, Conzo, Giovanni, additional, Flagiello, Luigi, additional, Gambardella, Claudio, additional, Lucido, Francesco Saverio, additional, Brusciano, Luigi, additional, Parisi, Simona, additional, De Bortoli, Nicola, additional, Savarino, Edoardo Vincenzo, additional, Del Genio, Gianmattia, additional, and Docimo, Ludovico, additional

Published
2024
Full Text
View/download PDF

46. Eosinophilic esophagitis in adults and adolescents: epidemiology, diagnostic challenges, and management strategies for a type 2 inflammatory disease

Author

Savarino, Edoardo Vincenzo, primary, Barbara, Giovanni, additional, Bilò, Maria Beatrice, additional, De Bortoli, Nicola, additional, Di Sabatino, Antonio, additional, Oliva, Salvatore, additional, Penagini, Roberto, additional, Racca, Francesca, additional, Tortora, Annalisa, additional, Rumi, Filippo, additional, and Cicchetti, Americo, additional

Published
2024
Full Text
View/download PDF

48. Nursing Interventions Targeting Fatigue in Inflammatory Bowel Disease: A Systematic Review.

Author

Martinato, Matteo, Boffo, Elena, Lorenzon, Greta, Monaco, Eleonora, Iervolino, Clara, Comoretto, Rosanna Irene, Savarino, Edoardo Vincenzo, and Gregori, Dario

Subjects
INFLAMMATORY bowel disease treatment, NURSING care plans, MEDICAL quality control, FATIGUE (Physiology), CINAHL database, MEDICAL care, QUESTIONNAIRES, NURSING interventions, PROBLEM solving, ANXIETY, PSYCHOLOGICAL adaptation, DESCRIPTIVE statistics, INFLAMMATORY bowel diseases, SYSTEMATIC reviews, MEDLINE, MEDICAL databases, QUALITY of life, ONLINE information services, PSYCHOLOGICAL tests, MEDICAL care costs, MENTAL depression, BEHAVIOR therapy
Abstract

A prevalent symptom among Inflammatory Bowel Disease (IBD) patients is fatigue, characterized by a persistent sense of energy depletion that affects all aspects of daily life. This review aims to evaluate nursing interventions reported in the literature to alleviate fatigue in IBD patients. A comprehensive search was conducted across four electronic databases—PubMed, CINAHL, Cochrane, and Scopus—and four scientific journals: "Gastroenterology", "Inflammatory Bowel Disease", "Journal of Crohn's and Colitis", and "United European Gastroenterology Journal". Inclusion criteria were clinical trials involving adult IBD patients in remission or mild disease activity. Out of 234 studies, 2 were selected for review. These studies assess the effectiveness of Solution-Focused Therapy (SFT) that emphasizes solving problems and developing strategies for improvement, and Problem-Solving Therapy (PST) that focuses on identifying problems and coping strategies. SFT showed a positive impact on fatigue with a significant improvement in the Checklist Individual Strength after three months: 45.5% in the control group, 85.7% in the SFT group, and 60% in the PST group, but its impact declined over time. Additionally, SFT demonstrated potential for reducing healthcare costs compared to standard of care and PST. Further research is needed to provide nurses interventions for managing fatigue in IBD patients. The review protocol has been registered at OSF.io. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. Enhancing Oral 5-ASA Effectiveness in Mild-to-Moderate Ulcerative Colitis through an H. erinaceus -Based Nutraceutical Add-on Multi-Compound: The "HERICIUM-UC" Two-Arm Multicentre Retrospective Study.

Author

Tursi, Antonio, D'Avino, Alessandro, Brandimarte, Giovanni, Mocci, Giammarco, Pellegrino, Raffaele, Savarino, Edoardo Vincenzo, and Gravina, Antonietta Gerarda

Subjects
ULCERATIVE colitis, DISEASE remission, HERICIUM erinaceus, CALPROTECTIN, NIACIN
Abstract

Mild-to-moderate ulcerative colitis (UC) management is centred on 5-aminosalicylic acid (5-ASA) derivatives. Whether supplementing 5-ASA with nutraceuticals can provide real advantages in UC-relevant outcomes is unclear. This retrospective multicentre study compared clinical remission, response rates, and faecal calprotectin levels in a two-arm design, including patients treated with 5-ASA alone and those with additional H. erinaceus-based multi-compound supplementation. In the 5-ASA alone group, clinical response rates were 41% at three months (T1) and 60.2% at six months (T2), while corresponding clinical remission rates were 16.9% and 36.1%. In the nutraceutical supplementation group, clinical response rates were 49.6% (T1) and 70.4% (T2), with clinical remission rates of 30.4% (T1) and 50.9% (T2). No significant differences in clinical response rates between the groups at T1 (p = 0.231) and T2 (p = 0.143) emerged. Clinical remission rates differed significantly at both time points (p = 0.029 and p = 0.042, respectively). Faecal calprotectin levels decreased significantly in both groups during the retrospective follow-up (p < 0.05), and this was more pronounced in nutraceutical supplementation patients at both T1 (p = 0.005) and T2 (p = 0.01). No adverse events were reported. This multi-component nutraceutical supplementation offers real-world potential in controlling disease activity in patients with mild-to-moderate UC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

50. Gemini-Assisted Deep Learning Classification Model for Automated Diagnosis of High-Resolution Esophageal Manometry Images.

Author

Popa, Stefan Lucian, Surdea-Blaga, Teodora, Dumitrascu, Dan Lucian, Pop, Andrei Vasile, Ismaiel, Abdulrahman, David, Liliana, Brata, Vlad Dumitru, Turtoi, Daria Claudia, Chiarioni, Giuseppe, Savarino, Edoardo Vincenzo, Zsigmond, Imre, Czako, Zoltan, and Leucuta, Daniel Corneliu

Subjects
ESOPHAGEAL motility disorders, IMAGE recognition (Computer vision), ARTIFICIAL intelligence, DEEP learning, IMAGE analysis
Abstract

Background/Objectives: To develop a deep learning model for esophageal motility disorder diagnosis using high-resolution manometry images with the aid of Gemini. Methods: Gemini assisted in developing this model by aiding in code writing, preprocessing, model optimization, and troubleshooting. Results: The model demonstrated an overall precision of 0.89 on the testing set, with an accuracy of 0.88, a recall of 0.88, and an F1-score of 0.885. It presented better results for multiple categories, particularly in the panesophageal pressurization category, with precision = 0.99 and recall = 0.99, yielding a balanced F1-score of 0.99. Conclusions: This study demonstrates the potential of artificial intelligence, particularly Gemini, in aiding the creation of robust deep learning models for medical image analysis, solving not just simple binary classification problems but more complex, multi-class image classification tasks. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results